IQVIA Holdings Inc

IQVIA Holdings leads health‑data analytics, empowering pharma with real‑world insights for drug development, regulatory success, and resilient supply chains across a $2.6 trillion global market.

IQVIA’s AI strategy faces scrutiny as TD Cowen cuts its target, while a partnership with Isdin could unlock consumer‑health growth – can the company monetize AI amid regulatory pressure?

IQVIA Holdings’ analyst buzz: bullish growth‑fund buy, mixed bank targets, and a data‑science edge that investors eye for next‑quarter earnings.

IQVIA Q4 2025 earnings outlook: analysts predict modest revenue growth but stronger EPS; institutional investors shift positions amid early‑February price moves.

IQVIA’s share price climbs to the upper‑mid $230s, driven by a positive earnings outlook and a data‑driven clinical development strategy that blends real‑world evidence with molecular biology.

IQVIA Holdings Inc. boosts earnings with AI‑driven market‑access tools and growing clinical‑trial services, targeting a 45% market share and $1.2 bn 2024 revenue.

IQVIA Holdings Inc. shows how data‑driven platforms—molecular biology, AI, RWE—boost clinical trials and market success, driving growth in the life‑sciences services sector.

IQVIA Holdings: How robust data‑analytics and regulatory savvy keep the life‑sciences tech leader in a strong growth trajectory while navigating emerging DCTs, privacy rules and AI transparency challenges.

IQVIA’s steady rise in a volatile life‑sciences tech market hinges on AI‑powered data integration, patient‑retention analytics, and blockchain‑enabled compliance, driving 6% revenue growth and 24% EBITDA margin toward 2026.

IQVIA refines debt, cuts interest, and faces Belgian regulatory probe—boosting margins and market‑access plans while navigating competition scrutiny.